[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Clementi et al., 2017 - Google Patents

Entry inhibition of HSV-1 and-2 protects mice from viral lethal challenge

Clementi et al., 2017

View PDF
Document ID
4413162326609896639
Author
Clementi N
Criscuolo E
Cappelletti F
Quaranta P
Pistello M
Diotti R
Sautto G
Tarr A
Mailland F
Concas D
Burioni R
Clementi M
Mancini N
Publication year
Publication venue
Antiviral research

External Links

Snippet

The present study focused on inhibition of HSV-1 and-2 replication and pathogenesis in vitro and in vivo, through the selective targeting of the envelope glycoprotein D. Firstly, a human monoclonal antibody (Hu-mAb# 33) was identified that could neutralise both HSV-1 and-2 at …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus, e.g. cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Similar Documents

Publication Publication Date Title
Petro et al. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease
Krawczyk et al. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus
Antoine et al. Glycoprotein targeted therapeutics: a new era of anti‐herpes simplex virus‐1 therapeutics
US9657088B2 (en) Anti-HSV antibody
Srivastava et al. CXCL10/CXCR3-dependent mobilization of herpes simplex virus-specific CD8+ TEM and CD8+ TRM cells within infected tissues allows efficient protection against recurrent herpesvirus infection and disease
Takahashi et al. Varicella-zoster virus infection induces autophagy in both cultured cells and human skin vesicles
RU2703903C2 (en) Local application of hsv antibody
Du et al. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus
US11472867B2 (en) Anti-HSV GB monoclonal antibody or antigen-binding fragment thereof
Clementi et al. Entry inhibition of HSV-1 and-2 protects mice from viral lethal challenge
Clementi et al. Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes
Ramsey et al. A single-cycle glycoprotein D deletion viral vaccine candidate, ΔgD-2, elicits polyfunctional antibodies that protect against ocular herpes simplex virus
Bauer et al. Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections
US10899824B2 (en) Anti-HSV synergistic activity of antibodies and antiviral agents
US10626167B2 (en) Human monoclonal antibodies endowed with strong neutralizing activity against HSV-1 and HSV-2
Backes et al. Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections
Tian et al. A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D
He et al. Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody
US20230111803A1 (en) Method of treating and preventing ocular disease with hsv-2 delta gd
Slein et al. Antibody effector functions are required for broad and potent protection of neonates from herpes simplex virus infection
CN116964103A (en) Broad-spectrum antibody of SARS-CoV-2 virus and its application
Croia et al. FRI0259 Ectopic lymphoid structures support epstein-barr virus persistence and autoreactive plasma cell infection in sjogren’s syndrome salivary glands
Hillen et al. FRI0258 Decreased tslp expression in labial salivary glands of patients with primary sjögren’s syndrome is associated with increased t and b cell inflammation and tissue destruction